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ABSTRACT 
MODY2 (mature onset diabetes of the young, type2) is associated with 
mutations in the GCK gene that result in impaired glucokinase activity. Although 
more than 200 inactivating GCK mutations have been reported, only less than 
20% of these mutations have been functionally characterized. In this work we 
describe the biochemical characterization of six missense glucokinase 
mutations associated to MODY2 from Spanish patients, namely Y61S, V182L, 
C233R, E265K, A379V and K420E. All these mutations produced enzymes that 
presented reduced enzymatic activity in various degrees, from a mild affectation 
(K420E) to a more severe effect (C233R). The severity of the mutation 
correlated with the importance of the structural changes introduced by the 
mutations. For example, the C233R affected a critical residue of the active 
centre of the enzyme and rendered a protein with undetectable enzymatic 
activity. These data add new information on the structure-function relationship 
of human glucokinase. 
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INTRODUCTION 
Glucokinase B (GlkB, hexokinase IV) is the first enzyme of the glycolytic 
pathway in pancreatic -cells. It phosphorylates the glucose that enters these 
cells through the GLUT2 glucose transporter to produce Glu-6P, which is then 
used to obtain the energy necessary for cell viability. The kinetic properties of 
GLUT2 (high capacity, low-affinity glucose transporter) and GlkB (low affinity for 
glucose and absence of allosteric regulation by Glu-6P) define GlkB as the key 
regulator of glucose consumption. For this reason, several authors have 
considered GlkB as the “glucose sensor” of pancreatic -cells [(Matschinsky et 
al. 1993), (Matschinsky 1996), (Matschinsky et al. 1998), (Matschinsky 2002), 
(Zelent et al. 2005)]. In addition, a positive correlation between the functionality 
of GlkB and the ability of pancreatic -cells to respond to increased levels of 
glucose in blood by enhancing insulin production and secretion has been 
described. In this way, GlkB participates in maintaining the blood glucose 
concentration around 5 mM. Mutations in glucokinase gene (GCK) that increase 
the affinity of the enzyme for glucose decrease the threshold for glucose 
stimulated insulin secretion (GSIS) and therefore trigger insulin secretion at 
lower concentrations of glucose in blood. These mutations are associated with 
both, mild and severe forms of persistent hyperinsulinaemic hypoglycaemia in 
infancy (PHHI-GK). On the other hand, inactivating mutations in one or both 
alleles of glucokinase gene leads to an enzyme with low activity which will 
increase the threshold for glucose stimulated insulin secretion (GSIS) from its 
physiological setting of 5 mM. These type of mutations are associated with a 
mild form of diabetes mellitus in young people, known as maturity onset 
diabetes of the young type 2 (MODY2), or with severe permanent neonatal 
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diabetes mellitus (PNDM) [see (Matschinsky 2002), (Zelent et al. 2005) and 
(Gloyn 2003), for review]. 
MODY2 is a form of diabetes mellitus characterized by an onset that 
usually appears before 25 years of age and abnormal -cell function and insulin 
secretion (Velho et al. 2004). The MODY2 phenotype is characterized by a mild, 
non-progressive form of hyperglycemia present from birth, often asymptomatic 
and only detected later in life. MODY2 patients are usually treated with diet 
alone and rarely develop diabetic-associated complications (Velho et al. 2004). 
Nearly 200 mutations have been already identified as inactivating GCK 
mutations. They are almost evenly distributed along the 10 exons that comprise 
the GCK gene and include missense, nonsense and frameshift mutations 
produced by deletions or insertions. However, only less than 20% of these 
mutations have been functionally characterized [(Gloyn 2003), (Velho et al. 
2004), (Gloyn et al. 2004)]. Despite considerable differences in the effect of the 
mutations on the in vitro activity of the enzyme, it is generally accepted that the 
MODY2 phenotype is quite homogeneous [(Miller et al. 1999), (Stride et al. 
2002)]. 
 The crystal structure of human GlkB has been recently characterized 
(Kamata et al. 2004). These results indicate that the protein has a large and a 
small domain, separated by a deep cleft. Glucose binds to the interdomain cleft, 
composed of residues of the large domain (Glu256 and Glu290), the small 
domain (Thr168 and Lys169) and the connecting region I (Asn204 and Asp205). 
Upon binding to substrates (glucose and ATP), GlkB undergoes a 
conformational change that brings the large and the small domain physically 
closer, resulting in a closed, active conformation. This structural model has 
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helped in the understanding of the abnormal biochemistry of different GCK 
missense mutations [(Pedelini et al. 2005), (Galan et al. 2006)]. 
 In this study we report the biochemical characterization of six GCK 
missense mutations found in Spanish MODY2 families (Estalella et al. 2007) 
and evaluated the impact of the mutation at the structural level by introducing 
these modifications into the closed active and super-open inactive GlkB 
structure models described recently (Kamata et al. 2004). 
 
MATERIALS AND METHODS 
1.- Subjects 
A total of 21 subjects from 9 families (Estalella et al. 2007) with one of 
the following six GCK mutations (Y61S, V182L, C233R, E265K, A379V and 
K420E) were included in this study. These mutations were selected among the 
different mutations identified in the previous study (Estalella et al. 2007) 
because they were novel missense mutations (except E265K) that were 
representative of different areas of the molecular structure of glucokinase. All 
the patients met the classical MODY2 diagnostic criteria, presenting a defect in 
glucose homeostasis, absence of autoimmunity markers and an autosomal 
dominant mode of inheritance (Velho and Froguel 1997). The human ethic 
committee of Cruces hospital approved the study and all analyses were 
performed after informed consent was obtained from individuals or their 
parents. 
 
2.- Site directed mutagenesis 
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 All the mutants used in this study were obtained as described in (Pedelini 
et al. 2005) using the QuickChange site-directed mutagenesis kit from 
Stratagene (La Jolla, CA) and the oligonucletides described in Table 1.  
 
3.- Purification of GST-fusion proteins and kinetic determinations 
 Purification of the mutated GST-GlkB fusion proteins was carried out as 
described in (Pedelini et al. 2005). The kinetic parameters of the recombinant 
GST-GlkB proteins were also measured as described in (Pedelini et al. 2005). 
 
4.- Prediction of structural effects of glucokinase mutations. 
 Crystal coordinates from the closed active (1V4S) and super-open 
inactive (1V4T) conformation of GlkB (Kamata et al. 2004) were visualized and 
mutations evaluated using O program (Jones and Kjeldgaard 1997). Figure 2 
was generated with MolScript (Kraulis 1991) and Render 3D (Merritt and Bacon 
1997) programs using the original or O-program modified PDBs. 
 
RESULTS AND DISCUSSION 
Kinetic parameters of novel GCK missense mutations 
Selected missense mutations from Spanish MODY2 families (Y61S, 
V182L, C233R, E265K, A379V and K420E; see Table 2) were introduced in 
GCK cDNA by site-directed mutagenesis, using appropriated oligonucleotides. 
Mutated cDNAs were subcloned into plasmid pGEX6P-1 to produce GST-GlkB 
proteins that were purified from bacteria. We then compared the kinetic 
parameters of the mutated forms with those of the wild type glucokinase (Table 
2 and Fig. 1A). Since in regular conditions of glucose homeostasis the 
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concentration of glucose in human blood is around 5 mM and there are 
saturating concentrations of ATP, we assumed that the activity of the enzyme at 
5 mM glucose and saturating concentrations of ATP (5 mM) is a good 
parameter to correlate the activity of the enzyme with its performance under 
physiological conditions (Pedelini et al. 2005) (Fig. 1B). All the six missense 
mutations presented reduced enzymatic activity, in various degrees, from a mild 
affectation to a more severe effect. The K420E mutation was the milder; it had a 
lower glucose affinity (S0.5: 11.6 mM) in comparison to wild type (S0.5: 7.6 
mM). Interestingly, the activity of the mutated form at 5 mM glucose was almost 
half of wild type, suggesting a poor performance as a glucose phosphorylating 
enzyme under physiological conditions (Fig. 1B). 
The E265K and A379V mutations had affected both Vmax (37.9 and 28.7 
Units/mg, respectively) and S0.5 (11.5 mM and 13.7 mM, respectively). In 
addition, A379V had also a lower ATP affinity (Km 0.69 mM). The activity of the 
E265K mutated form at 5 mM glucose was also half of the wild type, whereas 
the activity of the A379V mutated form was even poorer (Fig. 1B). 
Mutations V182L and Y61S affected severely glucose affinity (S0.5: 28.8 
mM and 39.2 mM, respectively) and the Vmax of the mutated forms (16.7 and 
7.2 Units/mg, respectively). Both mutations increased the ATP affinity (KmATP: 
0.16 and 0.21 mM, respectively). The activity of the mutated forms at 5 mM 
glucose was very poor (Fig 1B), suggesting that these enzymes had a very poor 
performance as glucose phosphorylating enzymes under physiological 
conditions. 
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Finally, when we assayed the activity of the C233R mutant we were 
unable to detect any activity, suggesting that this mutation had abolished the 
glucose phosphorylating activity of the enzyme. 
 
Prediction of structural effects of glucokinase mutations. 
To understand the changes in the kinetic parameters of the mutated 
enzymes, we evaluated the impact of the mutation at the structural level by 
introducing these modifications into the closed active and super-open inactive 
GlkB structure models described recently (Kamata et al. 2004). Fig. 2 shows the 
effects of the mutations on the closed active conformation of the enzyme. 
The K420 residue (Fig. 2F) is located in the 12 helix of the large domain 
and it is exposed to the solvent in both the closed and the super-open 
conformations. In the K420E mutation there is a change in the charge of the 
side chain (from the positive Lys to the negative Glu residue) and perhaps this 
may affect its interaction with other negatively charged residues in the 
surrounding such as E421 and E440. The E265 residue (Fig. 2D) is located also 
in the large domain and exposed to the solvent. The E265K mutation would 
affect putative interactions with residues of the 2 helix, such as E46 and R40. 
In has been recently characterized a closely related mutation G264S (Massa et 
al. 2001) which also has minor effects on the kinetics of the enzyme (S0.5: 9.76 
mM; KmATP: 0.48 mM) (Gloyn et al. 2004). Since at the structural level the 
modifications introduced by all these three mutations (K420E, E265K and 
G264S) are minor, perhaps this is the reason why the kinetic properties of the 
mutated enzymes are not greatly affected. Recently, the characterization of the 
E265K mutation was described. The authors suggested that although the 
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impact of the mutation was minor at the level of the kinetics of the enzyme, it 
strongly affected protein stability, suggesting a possible structural level defect of 
this mutant protein (Galan et al. 2006). 
The A379 residue (Fig. 2E) is located in the 11 helix of the large 
domain, at the back of the ATP binding site. Since this residue is very close to 
residues of the 12 helix (such as F419, R422 and F423), the increase in size 
of the side chain of the new valine residue in the A379V mutation would force a 
reorganization of this protein region. For this reason, the kinetic properties of 
the mutated enzyme should be more affected. It is worth to point out that a 
closely related mutation A378V has been recently described as a glucokinase 
mutation found in a case of permanent neonatal diabetes (Njolstad et al. 2003). 
The A378V is buried in the large domain hydrophobic core, and directly oriented 
towards the ATP binding site, showing the kinetics of the mutated enzyme a 
severe defect (S0.5: 584 mM; KmATP: 8.08 mM) (Gloyn et al. 2004). Both 
modest Ala to Val mutations reflect the importance of the correct disposition of 
the 11 helix, although the relative orientation of the residue has a different 
impact on the structure of the protein and consequently on the kinetics of the 
enzyme. 
The V182 residue (Fig. 2B) is located in the 4 helix base of the small 
domain, following a catalytic loop that is involved in glucose binding site 
formation. In the super-open conformation, the glucose molecule is absent, and 
consequently this loop is disorganized. The transition between super-open and 
closed conformations involves a ~90º displacement of the 4 helix, pivoting 
over its base (where V182 localizes), in order to accommodate the catalytic 
loop. The V182L mutation introduces a residue with bigger side-chain and 
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higher hydrophobicity that might disturb an area packed with the side chains of 
residues D160 and K161 (in the loop) and M202. In this way, it would 
destabilize the catalytic loop disposition in the closed conformation of the 
enzyme. Furthermore, the change V182L might interfere in the transition 
between the different catalytic conformations. For this reason the mutated 
protein should have lower Vmax and glucose affinity, and higher Hill number 
than wild type. The substitution of Val by a Met residue (V182M) has also been 
reported (Costa et al. 2000). In this case, the mutated enzyme also displays 
lower Vmax and lower glucose affinity (S0.5: 83.9 mM) than wild type (Gloyn et 
al. 2004). On the contrary, both V182L and V182M mutations displayed a higher 
ATP affinity (KmATP 0.16 and 0.10 mM, respectively). 
The Y61 residue (Fig. 2A) is located in the connexion between small and 
large domains. In the closed conformation, the bulky hydrophobic Tyr side chain 
may make hydrophobic interactions with surrounding residues, such as R63, 
V244 and M251, and a hydrogen bridge bond with E157 main chain oxygen, 
stabilizing the closed conformation of the enzyme. In the Y61S mutation, the big 
hydrophobic Tyr residue is changed to a small polar Ser residue that does not 
longer maintain these interactions, destabilizing the closed conformation of the 
enzyme. This would result in a decrease in the Vmax and the glucose affinity of 
the mutated enzyme. In a closely related mutation V62A (Njolstad et al. 1998), 
the kinetic parameters were similarly affected (S0.5: 27.4 mM; KmATP: 0.20 
mM) (Gloyn et al. 2004), suggesting that this area may play an important role in 
maintaining the closed conformation of the enzyme. Interestingly, a V62M 
mutation shows higher glucose affinity (S0.5: 4.88 mM), although the mutation 
was isolated from patients suffering hyperglycemia (Gloyn et al. 2005). 
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Finally, the C233 residue (Fig. 2C) is located in the 10 sheet that forms 
part of the hydrophobic interface between small and large domains in the base 
of the active centre of the enzyme (glucose binding site). In the C233R 
mutation, the new Arg residue has a huge side-chain in comparison with the 
small original Cys. To accommodate the new side-chain, an important 
reorganization in the surrounding area must occur, destabilizing the active 
centre, and consequently, affecting severely the activity of the enzyme. 
 
Phenotype/Genotype relationship 
 The clinical characteristics of the patients carrying the corresponding 
GCK mutations are shown in Table 3. To determine whether the degree of 
biochemical in vitro defect in glucokinase activity was related to phenotype 
severity, mutations were ordered according to the magnitude of the change in 
enzymatic activity. However, no differences were observed among patients 
regarding clinical characteristics. Average fasting plasma glucose (FPG) (6.95 ± 
0.8 mmol/l) was found in all the cases and was similar to previously reported 
values (Stride et al. 2002). Although most of the MODY2 patients required only 
diet for control, three of them were treated with oral hypoglycaemic agents 
(OHA) or insulin, and these patients carried severe changes in the in vitro 
glucokinase activity. However, as there were other patients carrying the same 
mutation that only required diet for control, we can not establish a clear 
relationship between the severity of the biochemical defect and the actual 
diagnosis and treatment. 
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In summary, our data confirmed that MODY2-associated glucokinase 
mutations can be due to modifications in conserved residues of the active site, 
as in the case of C233R, to modifications that distort the structure of the protein, 
as in the case of A379V, V182L and Y61S, or to modifications in residues of the 
periphery of the molecule that may disrupt interactions with other residues of 
the protein or with other interacting proteins, as in the case of K420E and 
E265K, as previously suggested ((Miller et al. 1999), (Velho and Froguel 1997)). 
These data add new information on the structure-function relationship of human 
glucokinase. 
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Table 1: Oligonucleotides used in this study. The modified codon is underlined. 
 
 
Name 
 
Sequence 
 
 
Y61S-1 
 
5’-CAGTGTGAAGATGCTGCCCACCTCCGTGCGCTCCACCCCAGAAGG-3´ 
 
Y61S-2 
 
5´-CCTTCTGGGGTGGAGCGCACGGAGGTGGGCAGCATCTTCACACTG-3´ 
 
V182L-1 
 
5´-GGAGCAGAAGGGAACAATGTCTTGGGGCTTCTGCGAGACGCTATC-3´ 
 
V182L-2 
 
5´-GATAGCGTCTCGCAGAAGCCCCAAGACATTGTTCCCTTCTGCTCC-3´ 
 
C233R-1 
 
5´-GGCACGGGCTGCAATGCCCGCTACATGGAGGAGATGCAGAATGTG-3´ 
 
C233R-2 
 
5´-CACATTCTGCATCTCCTCCATGTAGCGGGCATTGCAGCCCGTGCC-3´ 
 
E265K-1 
 
5´-GCCTTCGGGGACTCCGGCAAGCTGGACGAGTTCCTGCTGGAGTATG-3´ 
 
E265K-2 
 
5´-CATACTCCAGCAGGAACTCGTCCAGCTTGCCGGAGTCCCCGAAGGC-3´ 
 
A379V-1 
 
5´-GAGAGCGTGTCTACGCGCGCTGTGCACATGTGCTCGGCGGGGCTGG-3´ 
 
A379V-2 
 
5´-CCAGCCCCGCCGAGCACATGTGCACAGCGCGCGTAGACACGCTCTC-3´ 
 
K420E-1 
 
5´-GTACAAGCTGCACCCCAGCTTCGAGGAGCGGTTCCATGCCAGCGTG-3´ 
 
K420E-2 
 
 
5´-CACGCTGGCATGGAACCGCTCCTCGAAGCTGGGGTGCAGCTTGTAC-3´ 
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Table 2: Kinetic parameters of mutated forms of glucokinase. Glucose-
dependent activity (Vmax, S0.5, Hill number) and ATP-dependent activity (Km) 
parameters were determined in purified GST-GlkB fusion proteins. Values are 
the mean of at least two different kinetic determinations for each purification 
procedure for each mutant ± standard deviation. The nucleotide change and the 
exon location for each mutant is also indicated. N.d. not detectable. 
 
 
 
Nucleotide 
change 
 
 
 
Exon 
 
Amino 
acid 
change 
 
 
Vmax 
(Units/mg) 
 
 
S0.5 
(mM) 
 
 
Hill 
number 
 
 
Km ATP 
(mM) 
   
Wild type 
 
44.1 ± 2.0 
 
7.6± 0.3 
 
1.42 ± 0.04 
 
0.45 ± 0.03 
TAC>TCC 2 Y61S 7.2 ± 0.6 39.2 ± 0.3 1.50 ± 0.17 0.21 ± 0.01 
GTG>TTG 5 V182L 16.7 ± 0.1 28.8 ± 2.7 1.61 ± 0.05 0.16 ± 0.03 
TGC>CGC 7 C233R n.d. n.d. n.d. n.d. 
GAG>AAG 7 E265K 37.9 ± 3.2 11.5 ± 0.5 1.37 ± 0.07 0.40 ± 0.07 
GCG>GTG 9 A379V 28.7 ± 7.5 13.7 ± 0.1 1.45 ± 0.02 0.69 ± 0.13 
AAG>GAG 10 K420E 41.3 ± 5.7 11.6 ± 0.3 1.47 ± 0.04 0.41 ± 0.05 
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Table 3: Clinical characteristics of subjects with the different MODY2 mutations 
ordered by decreasing in vitro enzymatic activity. (IGT: impaired glucose 
tolerance; OHA: oral hypoglycemic agents; FPG: fasting plasma glucose; 2-h 
OGTT: plasma glucose 2 hours after an oral glucose tolerance test).  
 
 
Mutation 
 
Age 
 
Years since 
diagnosis 
FPG  
(mmol/l) 
2-h OGTT  
(mmol/l) 
HbA1c  
(%) 
Diagnosis 
 
Actual 
treatment 
K420E 10 5 6.4 10.2 6.4 IGT diet 
K420E 14 2 6.7 10.1 6.0 IGT diet 
K420E 68 - 6.8 10.5 - IGT diet 
K420E 44 29 6.0 10.9 - IGT diet 
E265K 25 17 7.2 - 7.2 Diabetes diet 
E265K 36 21 6.6 8.1  IGT diet 
E265K 39 20 7.8 - 6.5 Diabetes diet 
E265K 42 11 7.8 - 6.6 Diabetes diet 
A379V 39 9 7.4 12.1 - Diabetes diet 
A379V 39 16 5.7 12.5 5.7 Diabetes diet 
A379V 68 12 7.6 - - Diabetes diet 
V182L 10 7 7.5 - 5.6 Diabetes diet 
V182L 11 3 7.3 -  Diabetes diet 
V182L 21 11 7.1 9.5 6.8 Diabetes diet 
V182L 49 31 7.2 - 6,2 Diabetes OHA 
Y61S 27 23 7.5 11.4 5.7 Diabetes diet 
Y61S 45 10 7.8 - 5.8 Diabetes diet 
C233R 28 17 5.6 9.3 - IGT diet 
C233R 30 17 6.2 10.9 - IGT diet 
C233R 54 30 - - 5.1 Diabetes OHA 
C233R 62 17 - - - Diabetes insulin 
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Figure legends 
 
Fig. 1: Enzymatic functionality of the mutated forms of glucokinase. A) Glucose-
dependent activity of mutated forms of glucokinase. B) Specific activity of 
mutated forms of glucokinase at 5 mM glucose and saturating concentrations of 
ATP (5 mM) at 30ºC. A representative experiment of at least two different 
kinetic determinations for each purification procedure is shown in each case. 
 
Fig. 2: Effects of the mutations on the structure model of glucokinase. (A-F) The 
different mutations were studied at the structural level by introducing these 
modifications into the closed active GlkB structure model. Wild type residues 
are coloured in green, whereas the mutated residues are coloured in magenta. 
Interacting residues are coloured in orange. In some panels, the position of the 
glucose (Gluc) or the glucokinase activator (Act) molecules is also indicated. 
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